Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FUSION PROTEIN OF SERUM ALBUMIN AND PHYSIOLOGICALLY ACTIVE PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/080304
Kind Code:
A1
Abstract:
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell such as a CHO cell is normally used to express the physiologically active protein as a recombinant protein, thereby efficiently producing the physiologically active protein as a highly active recombinant protein. The fusion protein may be obtained by bonding the physiologically active protein to the amino-terminal side of the SA, or may be obtained by bonding the physiologically active protein to a carboxyl terminal. Further, said fusion protein can be a body coupled with a ligand or an antibody.

Inventors:
TAKAHASHI KENICHI (JP)
SUGANO YASUNORI (JP)
ONOUCHI TAKASHI (JP)
Application Number:
PCT/JP2023/036884
Publication Date:
April 18, 2024
Filing Date:
October 11, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
JAPAN CHEM RES (JP)
International Classes:
C12N15/62; C07K14/765; C07K16/00; C07K16/28; C07K19/00; C12N5/10; C12N9/16; C12N15/13; C12N15/14; C12N15/56; C12N15/63; C12P21/02
Domestic Patent References:
WO2018124121A12018-07-05
WO2023090409A12023-05-25
Foreign References:
JP2007522806A2007-08-16
Other References:
MATSUDA, JUNKO: "Significance of sphingolipid activator proteins-saposins and pro-saposin-in health and disease", JOURNAL OF JAPANESE BIOCHEMICAL SOCIETY, NIPPON SEIKAGAKKAI, TOKYO, JP, vol. 89, no. 6, 25 December 2017 (2017-12-25), JP , pages 808 - 819, XP009554110, ISSN: 0037-1017, DOI: 10.14952/SEIKAGAKU.2017.890808
Attorney, Agent or Firm:
YAMAMOTO, Yoshiki et al. (JP)
Download PDF: